Clinical study on Maixuekang Capsules combined with tirofiban in treatment of elderly acute coronary syndrome
Objective To explore the clinical efficacy of Maixuekang Capsules combined with tirofiban in treatment of elderly acute coronary syndrome. Methods Patients (94 cases) with elderly acute coronary syndrome in Wuhan Wuchang Hospital from March 2022 to January 2024 were randomly divided into control (47 cases) and treatment (47 cases) group. Patients in the control group were iv administered with Tirofiban Hydrochloride Injection dissolved in normal saline,50 μg/mL,once daily. Patients in the treatment group were po administered with Maixuekang Capsules on the basis of the control group,4 grains/time,three times daily. Patients in two groups were treated for 4 weeks. After treatment,the clinical evaluations were evaluated,the levels of vWF,VEGF,ET-1,CEC,TG,TC,LDL-C,HDL-C,IL-18,CysC-C,IL-6 and hs-CRP in two groups before and after treatment were compared. Results After treatment,the total effective rate in the treatment group (91.49％) was significantly higher than that in the control group (74.47％,P<0.05). After treatment,the levels of vWF,VEGF,ET-1,CEC,TG,TC,LDL-C,IL-18,CysC,IL-6,and hs-CRP were significantly reduced in two groups,while the levels of HDL-C were significantly increased (P<0.05),and compared with the control group,the levels of these indicators in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Maixuekang Capsules combined with tirofiban in treatment of elderly acute coronary syndrome has a definite effect. It can effectively improve the degree of ischemia and related symptoms of patients,and at the same time weaken the inflammatory reaction.
NETL
NSTL
万方数据
